Sheel Bio. (SHEEL)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• P/E of 8.48 and PEG of 0.09 suggest cheap valuation relative to recent growth.
• Sales growth of 93.71% and profit growth of 105.03% show strong momentum.
• Piotroski F-score of 7/9 indicates decent operational health.
• ROCE of 14.48% reflects acceptable capital efficiency.
• Promoter holding of 72.29% aligns owner-management interests.

Concerns

• Latest quarter net profit reported as ₹0 Cr on ₹22 Cr sales, raising earnings quality and consistency concerns.
• No book value, ROE, or debt/equity data available; balance sheet risk cannot be assessed.
• Zero dividend yield means investors rely entirely on capital appreciation.
• Microcap with a wide 52-week range of ₹37.80 to ₹73.40; high volatility and potential liquidity risk.

AI Analysis

When I look at Sheel Bio, the first thing that catches my eye is the price-to-earnings ratio of 8.48 and the reported sales and profit growth of 93.71% and 105.03%. A PEG ratio of 0.09 is striking; it suggests the market is paying very little for very rapid growth. But as Graham taught, growth is only as good as its dependability. The latest quarter shows sales of ₹22 Cr but net profit of ₹0 Cr, which makes me pause. A company can report high annual growth yet still have choppy quarters, and I cannot ignore that. The balance sheet is largely a blind spot: book value, return on equity, and debt-to-equity are all unavailable. I refuse to fabricate a margin of safety from missing numbers. ROCE of 14.48% is respectable, and the Piotroski F-score of 7/9 suggests the business is not falling apart on operating metrics. Promoter holding of 72.29% is high, which can be good if they are building value, but it also limits float and can make the stock swing sharply. At ₹43.70, the market cap is just ₹122 Cr, so this is a microcap. The 52-week range of ₹37.80 to ₹73.40 confirms the volatility. With zero dividend yield, any return must come from price appreciation. I do not need to act today. I would wait for a few more quarters of consistent profitability and better financial disclosure before treating Sheel Bio as a serious compounding machine.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer